Cavendish

70 days ago

Smarttech247- prize shits disgrace the AIM Casino, does nobody care about the rules any more?

Smarttech247 (S247) floated on the AIM Sewer as an “award winning” AI cybersecurity play raising 3.67 million pounds at 29.66p on December 15 2022 c/o Nomad SPARK. Less than three years later it says that it is delisting and its shares are just 2.75p. There is also a year to July 31 2025 trading update. Sales raced ahead but we are warned that margins were softer so, ignoring disposals, underlying EBITDA will be below forecast. Surely it knew this some time ago. What on earth is SPARK doing in not reminding its clients about timely disclosure rules? About AIM Rule 10?

87 days ago

Cavendish Women of Influence – oh please spare me from this piffle

Cavendish (CAV), then called FinnCap (FCAP), floated on the AIM Casino in December 2018 at 27p. Proforma pre-tax profits in the six months to 31 October 2018 were £4 million and founder and CEO Sam Smith stated she was on a “mission” to tackle an awful City culture of sexism, yadda, yadda, yadda. That woke crusading continues and in calendar 2024 pre-tax profits were just £700,000. The shares are now just 12.5p. Call me a reactionary old dinosaur but the City culture I find repellent is fat cats drawing vast salaries while destroying shareholder value.

113 days ago

Letter to the FCA and AIM Regulation: Investigation into Stuart Ashman and Skinbiotherapeutics PLC

I just cannot see how Skinbiotherapeutics (SBTX) did not lead investors up the garden path, by omission not act, ahead of the June 16 2025 placing raising £4.2 million at 17p. Heads really should roll and if Nomad Singer is too weak to act against disgraced CEO Stuart Ashman and the company I have written to both the FCA and the Oxymorons at AIM Regulation asking for an immediate enquiry.

149 days ago

Just when you thought the Cavendish coverage of Skins was utterly crap… Singers makes you look back to a golden past! Its numbers are all wrong!

The Singer’s initiation note on its corporate client Skinbotherapeutics(SBTX) is a curious piece of fish. For staters Singer’s makes it clear that it will not, under any circumstances, be made available to private investors it is for II’s and City HNWIs only. This is pointless.

216 days ago

Tom Winnifrith Bearcast: Feck you Steve O'Hara

Optibiotix (OPTI) shares are still cheap as I explained yesterday but O'Hara has sold more Skinbiotherapeutics (SBTX) shares and his weasel words, enabling of PI financial rape by Cavendish and cowardice on cost cuts have left me seething

270 days ago

The snake in the garden of Eden Research talks with forked tongue (again)

Founded just under 30 years ago and listed for almost a quarter of a century Eden Research (EDEN) battles with Blackbird (BIRD) for the title of AIM’s most jam tomorrow stock. Eden has only ever once turned an accounting profit for any half year and that was a result of a Panama Pump accounting fraud. It has now managed to send well over £40 million to money heaven, including the costs of sending me a stream of lawyers letters for exposing its naughtiness back in 2005. Today the snake in the garden of Eden speaks with a forked tongue as a new joint broker is appointed.

360 days ago

Cavendish on Skinbiotherapeutics: God save us from Ashman as his M&A hunger is not sated

Skinbiotherapeutics (SBTX) is very simple. If you believe that Croda could deliver £25 million GP or anywhere close to that as CEO Stuart Ashman has intimated the shares are stupendously cheap at 17.75p. Ashman needs to do nothing apart from deliver other corporate deals and more GP from his existing IP and no more shares need be issued. Hell’s teeth why issue shares now or indeed at twice or three times the price given that on Ashman’s Croda numbers the shares could easily be 100p or even 200p! But Ashman is a git.

495 days ago

Tom Winnifrith Bearcast: making Bara Brith, death threat for the Lemming & I really warm to buying high yield insurers and banks

I start with the Bara Brith, explaining what it is that Joshua and I have made and why. Photos tomorrow. Then it is onto insurers lie Legal & General (LGEN) as well as banks like NatWest (NWG) and, citing a real expert, I explain why I am increasingly tempted. Then it is onto the death threat for the Lemming Investor. It is to do with Skinbiotherapeutics (SBTX) and the perp is almost certainly one of those emboldened by Giles Balleny at Cavendish (CAV) who should now be truly ashamed for that. It makes me consider what Britain is becoming and how, if my circumstances were different, I’d be emigrating and will encourage all my kids to do just that. 

542 days ago

Cavendish on Skinbiotherapeutics – I know how keen it is on Skins comment being “open source” so here is its note & forecasts

I know how keen the moronic weasel Giles Balleny at Cavendish is on all material regarding Skinbiotherapeutics (SBTX) being “open source” and so since his employer’s research notes are only available to a select few I reproduce the note out today below to help him out. There is no need to thank me for sparing you from the charge of a double standard, Giles, you knob. However, the note which covers the crap Dermatonics deal, I fear, begs more questions than it answers.

553 days ago

Letter to AIM Regulation: Regarding Advanced Oncotherapy you are now taking the piss: Rules are rules aren’t they?

I am not talking about imaginary rules dreamt up by the wretched poltroon Giles Balleny at Cavendish and the bearded buffoon Stuart Ashman but real AIM Rules, specifically the one that if shares are suspended for more than six months because of a failure to publish accounts, those shares are slung off AIM. But sometimes they are not. I have written to the Oxymorons at AIM regulation regarding Advanced Oncotherapy (AVO), where I own 1 share allowing me to attend AGMs but have been a perennial bear.

553 days ago

musicMagpie Letter to AIM Regulation: statement needed

The Oxymorons at AIM Regulation maybe busy reading ESG porn or dealing with the antics of poltroon Giles Balleny at Cavendish. If they do have a spare moment they should consider why shares in musicMagpie (MMAG) have collapsed in recent days and be forcing a statement. I am 99 sure I know the reasons but it would be nice to have that confirmed. I have sent the letter below by email:

554 days ago

AIM Regulation and Stuart Ashman: the Oxymorons don’t answer the question and I persist

The bearded poltroon in charge of Skinbiotherapeutics (SBTX), where I remain a loyal shareholder, says that “rules are rules” and that AIM Regulation has insisted that he cannot do a video interview with me inside a paywall. That is a lie and I am now in dialogue with the Oxymorons who so far, as you can see, are evasive. For what it is worth, hapless moron Giles Balleny at Nomad Cavendish has already been shown to be lying by events elsewhere.

598 days ago

EXPOSE: The outright hypocrisy of Cavendish regarding research behind a paywall

Yesterday I exposed how Cavendish, the Nomad, to Skinbiotherapeutics (SBTX) had banned its boss Stuart Ashman from doing interviews with me as the videos would be behind a paywall. It gets worse, as a kind reader points out.

598 days ago

Tom Winnifrith Birthday Bearcast - 56 not out!

In today’s podcast I look at Skinbiotherapeutics (SBTX) and the bell-ends at Cavendish, Cellular Goods (CBX)< Premier Miton (PMI), Canadian Overseas Petroleum (COPL), UK Oil & Gas (UKOG), Burberry (BRBY) on behalf of road sweeper Chris Bailey, Chill Brands (CHLL) and Supply@ME Capital (SYME)

600 days ago

Breaking: Email Exchange with Stuart Ashman as his Nomad demands no more interviews

This is Orwellian and shows that Giles Balleny of Nomad Cavendish (formerly Finncrap & Cenkos pre merger) is either thick as pig shit or morally bankrupt or both. Given he works for Cavendish I reckon it is both. He has ordered Stuart Ashman of Skinbiotherapeutics (SBTX) to record no more videos with me.

655 days ago

Tom Winnifrith Bonus Bearcast: I am angry about the Skinbiotherapeutics placing, I am furious with greedy Stuart Ashman but am going in for open offer

In this bonus Bearcast, I explain why I am cutting my target price materially for Skinbiotherapeutics (SBTX) but still see this as a potential five bagger. I am furious with Stuart Ashman who is greedy and has not delivered. And I think the company’s broker, Cavendish, has a lot of questions to answer. I warn you that Matthew’s Dog and Catriona will love this podcast.